KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Finished Goods (2017 - 2023)

Biolife Solutions (BLFS) has disclosed Finished Goods for 8 consecutive years, with $10.7 million as the latest value for Q1 2023.

  • On a quarterly basis, Finished Goods rose 25.14% to $10.7 million in Q1 2023 year-over-year; TTM through Mar 2023 was $10.7 million, a 25.14% increase, with the full-year FY2022 number at $8.3 million, up 36.13% from a year prior.
  • Finished Goods was $10.7 million for Q1 2023 at Biolife Solutions, up from $8.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $10.7 million in Q1 2023 to a low of $3.0 million in Q2 2019.
  • A 5-year average of $7.3 million and a median of $7.1 million in 2020 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: surged 334.26% in 2019, then fell 9.84% in 2021.
  • Biolife Solutions' Finished Goods stood at $6.1 million in 2019, then rose by 10.56% to $6.7 million in 2020, then dropped by 9.84% to $6.1 million in 2021, then skyrocketed by 36.13% to $8.3 million in 2022, then grew by 29.48% to $10.7 million in 2023.
  • Per Business Quant, the three most recent readings for BLFS's Finished Goods are $10.7 million (Q1 2023), $8.3 million (Q4 2022), and $10.1 million (Q3 2022).